Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics Inc. director Gilbert S. Omenn reported receiving a grant of derivative securities in the form of stock options. On January 16, 2026, he was awarded 60,000 stock options (right to buy) with a stated exercise price of
Galectin Therapeutics (GALT) director granted stock options
Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026. The options have an exercise price of $3.04 per share and were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. According to the filing, the options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Amelio beneficially owns 60,000 stock options directly.
Galectin Therapeutics Inc. director Elissa J. Schwartz received a grant of stock options for 60,000 shares of common stock. The options were awarded on January 16, 2026 under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and an expiration date of January 16, 2036.
The filing states that these options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Schwartz beneficially owns 60,000 derivative securities in the form of stock options, held directly.
Galectin Therapeutics director and 10% owner Richard E. Uihlein reported equity awards from the company. On January 16, 2026, he received 60,000 stock options with an exercise price of
On the same date, he was also issued 13,158 shares of common stock at
Galectin Therapeutics Inc. President and CEO Joel Lewis, who also serves as a director, reported equity compensation activity involving the company’s common stock. On January 5, 2026, 56,332 shares of common stock were reported at a price of $3.88 per share, reflecting settlement of deferred stock units (DSUs) and related share withholding for taxes. Following the transaction, Lewis beneficially owned 776,260 shares directly, which represent shares underlying DSUs and common stock.
Under Lewis’s employment and Deferred Stock Unit Agreements, 80% of his compensation is paid in DSUs, with DSUs from the amended agreement settling in common stock, including a tranche on January 5, 2026. The filing also shows 2,000 shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which Lewis expressly disclaims beneficial ownership.
Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026. The company states that his resignation is not due to any disagreement with Galectin on its operations, policies, or practices, indicating an orderly governance change rather than a dispute-driven departure.
Galectin Therapeutics Inc. President and CEO Joel Lewis reported several equity transactions in company stock. On January 2, 2026, 84,000 shares of common stock were acquired at $0 per share upon vesting of Restricted Stock Units, and on the same day 18,571 shares were sold at a weighted average price of $4.1968 per share under a pre-arranged Rule 10b5-1 trading plan. Additional sales of 27,731 shares at a weighted average price of $3.9069 on January 5, 2026 and 37,698 shares at a weighted average price of $3.5772 on January 6, 2026 were also reported.
Following these transactions, Lewis directly beneficially owned 832,592 shares of Galectin Therapeutics common stock. The filing also notes 2,000 shares held in an account where he acts as custodian for a minor child under the Uniform Transfers to Minors Act, for which he disclaims beneficial ownership. The transactions involving multiple sale prices are reported using weighted average prices, with detailed breakdowns available on request.
Galectin Therapeutics Chief Financial Officer Jack W. Callicutt reported a series of equity transactions in early
Also on
Galectin Therapeutics Inc Chief Medical Officer Jamil Khurram reported vesting and sales of company common stock. On January 2, 2026, 60,000 shares of common stock were acquired at $0 upon vesting of previously granted restricted stock units, then 13,055 of those shares were sold at a weighted average price of $4.1968. Additional sales of 25,499 shares at a weighted average price of $3.8985 on January 5, 2026, and 21,446 shares at a weighted average price of $3.6466 on January 6, 2026, reduced his reported holdings to zero shares. The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025.
GALT shareholder Harold Shlevin filed a notice to sell up to 441,500 common shares, with an aggregate market value of 1,836,640, through Merrill Lynch on NASQ around 01/02/2026. The filing lists 64,472,792 common shares outstanding for the issuer. The planned sale shares were acquired via a 6,500-share open market purchase on 12/30/2024 and multiple stock option exercises between 2018 and 2024, including 60,000 shares on 01/23/2025. In the prior three months, Shlevin sold 159,000, 16,790, 19,793, 8,417 and 24,706 common shares in December 2025, with gross proceeds ranging from 52,541.90 to 943,448.33.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
